Embedded Files
Clinical, Nutritional, and behavioral outcomes of incretin-based obesity medications and their adjunct therapies
Clinical, Nutritional, and behavioral outcomes of incretin-based obesity medications and their adjunct therapies
Observational cohort studies assessing weight loss, nutritional status, eating behaviors, and patient-reported outcomes among individuals treated with incretin-based obesity management medications (OMMs) in real-world clinical settings within Israeli HMOs.
Leveraging large-scale real-world data from central health maintenance organizations (HMOs) in Israel, this collaborative research program evaluates clinical, nutritional, and behavioral outcomes associated with incretin-based pharmacotherapy and its adjunct behavioral support.
A key project under this program is a large-scale retrospective longitudinal study examining whether structured lifestyle counseling enhances outcomes among individuals treated with incretin-based OMMs. While pharmacological therapies such as liraglutide, semaglutide, and tirzepatide demonstrate substantial weight loss and cardiometabolic benefits, important clinical questions remain regarding the role of adjunct behavioral and lifestyle support in optimizing treatment effectiveness, adherence, body composition, and long-term metabolic health.
Using large-scale real-world electronic medical record (EMR) real world data, this study address critical evidence gaps regarding best practices for integrating behavioral support with incretin-based pharmacotherapy.
Findings from this program are expected to inform clinical guidelines, strengthen multidisciplinary obesity care models, and support the development of evidence-based, patient-centered strategies to optimize long-term obesity management outcomes.
Setting
Maccabi Healthcare Services, in collaboration with KSM – Kahn Sagol Maccabi.
Research Team and students involved
Mor Ben-Meleh
Supervision
Dr. Tair Ben-Porat
Dr. Rivka Rotstein
Status:
Analysis underway
Page updated
Report abuse